Csaba Kovesdy
Nephrology · Salem, VANPI 1477553022
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $133,706 of the $152,125 with a category attached, or 87.9%. 14 manufacturers reported payments, led by AstraZeneca at 28.2% of the total. Reporting peaked in 2022 at $45,939 and has fallen 76.2% since, to $10,912 in 2025. Among nephrology clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 143 payments — averaging $1063.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$43K
- Bayer$36K
- Boehringer Ingelheim$23K
- Akebia Therapeutics Inc$12K
- GSK$9K
- Eli Lilly$7K
- plus $22K from 8 others
Across 581 payments — averaging $2349.93 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bayer$394K
- Astrazeneca UK Limited$351K
- Akebia Therapeutics Inc$225K
- GSK$174K
- AstraZeneca$96K
- Gilead$47K
- plus $79K from 5 others
What the payments were for
- Consulting fees$133,70688%
- Speaking & faculty fees$2,0001%
- Travel & lodging$13,2719%
- Food & beverage$3,0012%
- Education$1460%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 57 | $42,925 |
| Bayer | 45 | $35,802 |
| Boehringer Ingelheim | 15 | $23,334 |
| Akebia Therapeutics Inc | 3 | $11,500 |
| GSK | 4 | $9,475 |
| Eli Lilly | 3 | $6,891 |
| Vifor Pharma, Inc. | 4 | $4,999 |
| CSL Behring | 2 | $3,678 |
| Rockwell Medical, Inc. | 1 | $3,675 |
| Amgen | 1 | $3,000 |
| Astrazeneca UK Limited | 2 | $2,556 |
| Ardelyx, Inc. | 1 | $2,310 |
| Pharmacosmos Therapeutics Inc. | 4 | $1,886 |
| Otsuka America Pharmaceutical, Inc. | 1 | $96 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerendia$30,490
- LOKELMA$27,983
- JARDIANCE$12,332
- AURYXIA$7,250
- Non-Covered$4,500
- TRIFERIC$3,675
- Parsabiv$3,000
- FARXIGA$2,065
- Monoferric$1,875
How this compares
$152,125 in reported general payments places this provider in the 95th percentile of 298 nephrology providers in Virginia.
Other nephrology in Salem
- Ramon MendezWoodbridge$791K
- Reza ZonoziFairfax$262K
- Sandeep MagoonNorfolk$204K
- Thomas McCuneNorfolk$202K
- Gaurav GuptaRichmond$168K
- Ramin TolouianNorfolk$115K
- Mahesh KrishnanMc Lean$115K
- Mitchell RosnerCharlottesville$105K
- Neeraja TandraReston$70K
- Renuka SothinathanFairfax$68K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.